Frequency modulation of ERK activation dynamics rewires cell fate H Ryu, M Chung, M Dobrzyński, D Fey, Y Blum, SS Lee, M Peter, ... Molecular systems biology 11 (11), 838, 2015 | 219 | 2015 |
Crosstalk and signaling switches in mitogen-activated protein kinase cascades D Fey, DR Croucher, W Kolch, BN Kholodenko Frontiers in physiology 3, 355, 2012 | 207 | 2012 |
The extracellular matrix as a key regulator of intracellular signalling networks JF Hastings, JN Skhinas, D Fey, DR Croucher, TR Cox British journal of pharmacology 176 (1), 82-92, 2019 | 188 | 2019 |
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients D Fey, M Halasz, D Dreidax, SP Kennedy, JF Hastings, N Rauch, ... Science signaling 8 (408), ra130-ra130, 2015 | 164 | 2015 |
Exact model reduction of combinatorial reaction networks H Conzelmann, D Fey, ED Gilles BMC systems biology 2 (1), 1-25, 2008 | 78 | 2008 |
The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells D Fey, D Matallanas, J Rauch, OS Rukhlenko, BN Kholodenko Seminars in cell & developmental biology 58, 96-107, 2016 | 75 | 2016 |
PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells S Rogers, D Fey, RA McCloy, BL Parker, NJ Mitchell, RJ Payne, RJ Daly, ... Journal of cell science 129 (7), 1340-1354, 2016 | 62 | 2016 |
Pseudophosphatase STYX modulates cell-fate decisions and cell migration by spatiotemporal regulation of ERK1/2 V Reiterer, D Fey, W Kolch, BN Kholodenko, H Farhan Proceedings of the National Academy of Sciences 110 (31), E2934-E2943, 2013 | 62 | 2013 |
Performance of objective functions and optimisation procedures for parameter estimation in system biology models A Degasperi, D Fey, BN Kholodenko NPJ systems biology and applications 3 (1), 20, 2017 | 61 | 2017 |
MASTL overexpression promotes chromosome instability and metastasis in breast cancer S Rogers, RA McCloy, BL Parker, D Gallego-Ortega, AMK Law, VT Chin, ... Oncogene 37 (33), 4518-4533, 2018 | 58 | 2018 |
Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma DJ Duffy, A Krstic, M Halasz, T Schwarzl, D Fey, K Iljin, JP Mehta, K Killick, ... Oncotarget 6 (41), 43182, 2015 | 38 | 2015 |
Polyubiquitin chain assembly and organization determine the dynamics of protein activation and degradation LK Nguyen, M Dobrzyński, D Fey, BN Kholodenko Frontiers in physiology 5, 4, 2014 | 37 | 2014 |
Frequency modulation of ERK activation dynamics rewires cell fate H Ryu, M Chung, M Dobrzyński, D Fey, Y Blum, S Sik Lee, M Peter, ... Molecular systems biology 12 (4), 866, 2016 | 33 | 2016 |
Wnt signalling is a bi-directional vulnerability of cancer cells DJ Duffy, A Krstic, T Schwarzl, M Halasz, K Iljin, D Fey, B Haley, J Whilde, ... Oncotarget 7 (37), 60310, 2016 | 32 | 2016 |
Parameter estimation in kinetic reaction models using nonlinear observers facilitated by model extensions D Fey, R Findeisen, E Bullinger IFAC Proceedings Volumes 41 (2), 313-318, 2008 | 24 | 2008 |
BAX and SMAC regulate bistable properties of the apoptotic caspase system S McKenna, L García-Gutiérrez, D Matallanas, D Fey Scientific reports 11 (1), 3272, 2021 | 23 | 2021 |
Accurate prediction of kinase-substrate networks using knowledge graphs V Nováček, G McGauran, D Matallanas, A Vallejo Blanco, P Conca, ... PLoS computational biology 16 (12), e1007578, 2020 | 23 | 2020 |
Applications of personalised signalling network models in precision oncology JF Hastings, YEI O'Donnell, D Fey, DR Croucher Pharmacology & Therapeutics 212, 107555, 2020 | 17 | 2020 |
Impact of measurement noise, experimental design, and estimation methods on modular response analysis based network reconstruction C Thomaseth, D Fey, T Santra, OS Rukhlenko, NE Radde, ... Scientific reports 8 (1), 16217, 2018 | 16 | 2018 |
Personalized computational models as biomarkers W Kolch, D Fey Journal of personalized medicine 7 (3), 9, 2017 | 16 | 2017 |